Not exact matches
«Our study suggests that ALDH1A3 is a potentially functional biomarker for mesenchymal
glioma stem
cells, and that
inhibiting that enzyme might offer a promising therapeutic approach for high - grade
gliomas that have a mesenchymal signature,» says principal investigator Ichiro Nakano, MD, PhD, associate professor of neurosurgery at the OSUCCC — James.
Inhibiting ALDH1A3 - mediated pathways slows the growth of mesenchymal
glioma stem
cells and might provide a promising therapeutic approach for glioblastomas with a mesenchymal signature.
They will follow this approach to design a novel treatment plan by rationally combining gemcitabine with
cell cycle checkpoint inhibitor, oxygen - enrich gas inhalation, and radiotherapy to significantly
inhibit the growth of aggressive
glioma.
They also investigated a new strategy to significantly
inhibit glioma growth by rationally combining gemcitabine and MK - 8776, a
cell cycle checkpoint inhibitor.